BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Imcivree (setmelanotide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Imcivree (setmelanotide)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06760546-123@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270313
DTEND;VALUE=DATE:20270314
SUMMARY:Imcivree (setmelanotide): Phase 3 readout est. (NCT06760546)
DESCRIPTION:Imcivree (setmelanotide)\, phase 3\, Obesity.\nStudy: A Trial o
 f Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-stud
 y of NCT05774756)\nEstimated primary completion: 13 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/setmelanotide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06760546
URL:https://assetmemo.bio/drug/setmelanotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07496463-123@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Imcivree (setmelanotide): Phase 2 readout est. (NCT07496463)
DESCRIPTION:Imcivree (setmelanotide)\, phase 2\, Obesity.\nStudy: Setmelano
 tide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (
 PHP1a)\nEstimated primary completion: 30 April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/setmelanotide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07496463
URL:https://assetmemo.bio/drug/setmelanotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674290-123@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Imcivree (setmelanotide): Phase 4 readout est. (NCT07674290)
DESCRIPTION:Imcivree (setmelanotide)\, phase 4\, Obesity.\nStudy: Real-Worl
 d Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity\nEstim
 ated primary completion: 31 December 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/setmelanotide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07674290
URL:https://assetmemo.bio/drug/setmelanotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
